MTOR and rheumatoid arthritis: Specifically, administration of the pan-PI3K/mTOR inhibitor gedatolisib yielded a comparable decrease in the activity of p-RPS6 and p-4EBP1 (by 71–76%) [90], while dual metabolic modulation resulted in a pronounced reduction in both viability and glycolytic activity of RA-FLSs, including diminished lactate production and proinflammatory cytokine release [91].